ClinicalTrials.gg
CompletedNCT01899742Updated Jan 24, 2018Results posted

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

A Phase 3 interventional study of Umeclidinium/Vilanterol 62.5/25 mcg and Tiotropium 18 mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 64 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
497
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
64th of 236
497 · median 101
Started
2014
with 18 others
Phase 3
65 of 276
5 open now
Registered
174th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 64th largest by enrollment of the 236 interventional ones that give a count, is one of 19 that started in 2014, is one of 65 in phase 3, and was the 174th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and continue to have symptoms while on tiotropium.

Read the detailed description

This is a Phase IIIb multicentre, randomized, blinded, double-dummy, parallel group study to evaluate the efficacy and safety of UMEC/VI Inhalation Powder (62.5/25 mcg) when administered once-daily via ELLIPTA dry powder inhaler (DPI) [note: the ELLIPTA DPI may also be referred to as the Novel DPI (NDPI) or the DPI] compared with tiotropium (18 mcg) administered once-daily via the HandiHaler over a treatment period of 12 weeks in subjects with COPD who continue to have symptoms while on tiotropium.

The target population of the study will include those subjects who continue to have symptoms while on tiotropium. The study will screen approximately 650 subjects who continue to have symptoms whilst on tiotropium. After a 4 week run-in period on open label tiotropium, those subjects who continue to have symptoms and have adhered to the treatment schedule will progress into the treatment phase.

At the end of the run-in phase approximately 490 subjects will be randomised 1:1 to UMEC/VI Inhalation Powder (62.5/25 mcg), or tiotropium (18 mcg). During the treatment phase, each subject will receive two inhalers, a preloaded ELLIPTA DPI and a HandiHaler dry powder inhaler with capsules, for once-daily administration of one active treatment and one placebo treatment for 12 weeks.

There will be a total of 8 study visits. Subjects will sign the informed consent form (ICF) at either Visit 0 or Visit 1 and will be assigned a subject identifier. Subjects who meet the eligibility criteria at Screening (Visit 1) will enter the open label tiotropium run-in phase. After 4 weeks all subjects will be reviewed (Visit 2) and if they satisfy the randomisation criteria they will be randomised and enter the treatment phase.

After Visit 2, there will be a further 6 study clinic visits. Further visits are scheduled at Day 2, Week 4, Week 8, Week 12 and Week 12 +1 day (Visits 3 to 7 respectively). Vital signs (blood pressure and pulse rate) will be obtained at all clinic visits.

Trough FEV₁and trough FVC will be performed at Visit 3 and Visit 7. Pre-dose and post dose FEV₁and FVC measurement at 5 and 15 mins and 1 and 3 hrs will also be performed at Visit 2, Visit 4, Visit 5 and Visit 6.

At selected study sites, a subset of approximately 200 subjects will perform 24-hour serial spirometry at Visit 2 and Visit 6 for evaluation of lung function over the dosing period.

An assessment of dyspnea will be obtained using the Baseline and Transition Dyspnea Index (BDI/TDI). At Visit 2, the severity of dyspnea at baseline will be assessed using the BDI. Change from baseline will be assessed using the TDI at Visit 4, Visit 5 and Visit 6.

In addition to the baseline assessment at Visit 2, health status will be captured using the St. George Respiratory Questionnaire for COPD (SGRQ-C) scale at Visit 4 and Visit 6.

The impact of COPD on the subject's wellbeing and daily life will be measured using the COPD Assessment Test (CAT) and the the Euroqol-5D (EQ5D).. In addition to the baseline assessment at Visit 2, the CAT and the EQ-5D will also completed at Visit 4 and Visit 6. Furthermore, the CAT is also completed during screening.

The Patient Global Rating of COPD Severity and Change of COPD Severity is a selfreported global assessment of severity of illness will be performed at Baseline during Visit 2 and at Visit 4 and Visit 6.

Visits 0/1 through 7 will be clinic visits conducted on an outpatient basis. A safety Follow-Up assessment (Visit 8) will be conducted either by phone call or clinic visit where required approximately 7 days after the end of the study treatment (Visit 7 or Early Withdrawal, if applicable). The total duration of subject participation, including follow-up, will be approximately 18 weeks. All subjects will be provided with albuterol/salbutamol for use on an "as-needed" basis throughout the run-in and study treatment periods.

For determination of subject disposition, subjects will be considered to have completed the study upon completion of Visit 7 (the last on-treatment clinic visit). There are no plans for compassionate use of the study medications.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient.
  • : A signed and dated written informed consent prior to study participation.
  • Age: Subjects 40 years of age or older at Visit 1.
  • Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of:

Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, >45 years, in the absence of hormone replacement therapy.

OR

Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact):

  • Abstinence
  • Oral Contraceptive, either combined or progestogen alone
  • Injectable progestogen
  • Implants of levonorgestrel
  • Estrogenic vaginal ring
  • Percutaneous contraceptive patches
  • Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label
  • Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records.
  • Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)

    • Bronchodilator Treatment: Subjects must have been prescribed tiotropium either via the HandiHaler device or Respimat for at least 3 months prior to screening (Visit 1).
    • Diagnosis: A diagnosis of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004].
    • Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack-years [number of pack years = (number of cigarettes per day /20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.

Note: Pipe and/or cigar use cannot be used to calculate pack-year history

  • Severity of Disease: A pre and post-albuterol/salbutamol /FVC ratio of \<0.70 and post-albuterol/salbutamol FEV₁ of ≤70% and ≥50% predicted normal values calculated using reference equations at Visit 1 [Quanjer, 2012].
  • Dyspnoea: A score of ≥1 on the Modified Medical Research Council Dyspnoea Scale (mMRC) at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: A current diagnosis of asthma.
  • Other Respiratory Disorders: Known α-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to should be excluded. Examples may include bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease. Allergic rhinitis is not exclusionary.
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \<5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Exacerbations: Has had more than 1 moderate or severe COPD exacerbation in the past 12 months. Subjects with a moderate exacerbation within 6 weeks or severe exacerbations within 10 weeks prior to Visit 1 are excluded from study.

A moderate COPD exacerbation is defined as worsening symptoms of COPD that require treatment with oral/systemic and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD that require in-patient hospitalization.

  • : A history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
  • 12-Lead : An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, including the presence of a paced rhythm on a 12-lead ECG which causes the underlying rhythm and ECG to be obscured. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. Specific ECG findings that preclude subject eligibility are listed in Appendix 3. The study investigator will determine the medical significance of any ECG abnormalities not listed in Appendix 3.

Appendix 3:

  • Sinus tachycardia ≥120 bpm. *Note: sinus tachycardia ≥120bpm should be confirmed by two additional readings at least 5 minutes apart.
  • Sinus bradycardia \<45bpm. *Note: Sinus bradycardia \<45bpm should be confirmed by two additional readings at least 5 minutes apart.
  • Multifocal atrial tachycardia.
  • Supraventricular tachycardia (>100bpm).
  • Atrial fibrillation with rapid ventricular response (rate >120bpm).
  • Atrial flutter with rapid ventricular response (rate >120bpm).
  • Ventricular tachycardias (non sustained, sustained, polymorphic, or monomorphic).
  • Ventricular flutter.
  • Ventricular fibrillation.
  • Torsades de Pointes.
  • Evidence of Mobitz type II second degree or third degree atrioventricular (AV) block.
  • AV dissociation.
  • 2:1 AV block.
  • Trifascicular Block.
  • For subjects with QRS duration \<120 ms: (F) ≥450msec or an ECG that is unsuitable for QT measurements (e.g., poor defined termination of the T wave).
  • For subjects with QRS duration≥120: QTc(F) ≥480msec or an ECG that is unsuitable for QT measurements (e.g., poor defined termination of the T wave).
  • Myocardial infarction (acute or recent) * Note: Evidence of an old (resolved) myocardial infarction is not exclusionary

    • Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
    • Medications Prior to Screening: Use of the following medications according to the following defined time intervals prior to Visit 1.

Use as maintenance treatment in the 3 months prior to Visit 1 is not permitted. Maintenance treatment is defined as use for ≥ 14 consecutive days (at any time in the 3 months prior to Visit 1).

  • Inhaled Corticosteroid (ICS)/Inhaled long acting beta2-agonists combinations
  • Phosphodiesterase 4 (PDE4) inhibitors
  • LABA
  • Other Long acting muscarinic antagonists (does not include tiotropium)
  • LAMA/LABA combinations
  • Theophyllines
  • Oral beta2-agonists (long-acting and short-acting) Use within 12 weeks is not permitted.
  • Depot corticosteroids Use within 6 weeks is not permitted.
  • Systemic, oral or parenteral corticosteroids
  • Antibiotics (for lower respiratory tract infection)
  • Cytochrome P450 3A4 strong inhibitors Use within 4 hours is not permitted.
  • Inhaled short acting beta2-agonists, short-acting anticholinergics, and short-acting anticholinergic/short- acting beta2-agonist combination products (Use of study provided prn albuterol/salbutamol is permitted during the study, except in the 4-hour period prior to spirometry testing. Subjects who are taking short acting bronchodilators (beta-agonists or muscarinic antagonists) as their only form of bronchodilation at screening may NOT be recruited into the study).

Any other medication use within 30 days or within 5 drug half-lives (whichever is longer) is not permitted

Note: if a LABA, LAMA (non-tiotropium), ICS/LABA, LAMA/LABA, theophylline, oral beta-agonist,or PDE4 inhibitor was taken on a non-maintenance basis (i.e., \< 14 consecutive days over the 3 months prior to screening) the following minimum washouts must be observed prior to visit 1: twice-daily LABAs and ICS/LABAs = 48 hours; once-daily LABAs and ICS/LABAs= 14 days; LAMAs (excluding tiotropium) = 7 days; once-daily LAMA/LABA = 14 days, twice-daily LAMA/LABA = 7days; theophyllines = 48 hours; oral beta2 agonists = 48 hours; PDE4 inhibitor = 14 days.

  • Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., ≤12 hours per day) is not exclusionary.
  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy.
  • Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 12 weeks prior to Visit 1 or are in the maintenance phase of a pulmonary rehabilitation program are excluded.
  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.
  • Inability to Read: In the opinion of the investigator, any subject who is unable to read and/or write would not be able to complete a questionnaire.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
497 participants (actual)

Study arms

  • Experimental
    Umeclidinium/Vilanterol

    Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)

    Drug: Umeclidinium/Vilanterol 62.5/25 mcg

  • Active comparator
    Tiotropium

    Long-acting muscarinic antagonist (LAMA)

    Drug: Tiotropium 18 mcg

Interventions

  • DrugUmeclidinium/Vilanterol 62.5/25 mcg

    Inhalation Powder

  • Inhalation Powder

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Visit 8)

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in 1 second. BL was the mean of the values measured 23 hour and 24 hour after dosing prior to Day 1 (ie. after the last open label \[OL\] tiotropium dosing and prior to the randomized dose). Change from BL is defined as the post-BL value minus the BL value. Trough FEV1 on Day 85 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after dosing on Day 84 (at Week 12 + 1 day). Analysis performed using a mixed repeated measures model (MMRM) with covariates of treatment, BL, center group, 24 hour subset flag, Day, Day by BL and Day by treatment interactions. ITT Population is defined as participants who received at least one dose of randomized study medication in the treatment period. Only those participants with data available at the specified time point were included in the analysis.

    Time frame: Baseline (BL) and Day 85

Secondary outcomes

  1. Change From BL in FEV1 at 3 Hours Postdose on Day 84

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in 1 second. FEV1 assessments taken on 0 to 3 hour on Day 84 (pre-dose, 5 minutes (min), 15 min, 30 min, 1 hour, and 3 hour post-dose). Pre-dose was the reading obtained at 24 hours after the previous day's dose (Day 83 dose). BL is defined as mean of the values measured 23 hour and 24 hour after dosing prior to Day 1 (ie. after the last OL tiotropium dosing and prior to the randomized dose). Change from BL is defined as the post-BL value minus the BL value. Analysis performed using mixed model repeated measures with covariates of treatment, BL FEV1, center group, 24 hour subset flag, time, time by treatment interaction and time by BL interaction. Only those participants with data available at the specified time point were included in the analysis.

    Time frame: Baseline and Day 84

07

Results

Posted Feb 25, 2016

Participant flow

Eligible participants (par) completed a 4-week open label tiotropium run-in phase, and were randomized to blinded study medication for 12 weeks. Supplemental albuterol/salbutamol was provided to all par, to be used on an as-needed basis during the run-in phase and up to Day 85.

Participant flow — Overall Study
MilestoneUmeclidinium/Vilanterol 62.5/25 µgTiotropium Bromide 18 µg
Started247247
Completed230231
Not completed1716
Withdrew: Adverse event54
Withdrew: Lack of efficacy15
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject95

Outcome measures

PrimaryChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Visit 8)

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in 1 second. BL was the mean of the values measured 23 hour and 24 hour after dosing prior to Day 1 (ie. after the last open label \[OL\] tiotropium dosing and prior to the randomized dose). Change from BL is defined as the post-BL value minus the BL value. Trough FEV1 on Day 85 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after dosing on Day 84 (at Week 12 + 1 day). Analysis performed using a mixed repeated measures model (MMRM) with covariates of treatment, BL, center group, 24 hour subset flag, Day, Day by BL and Day by treatment interactions. ITT Population is defined as participants who received at least one dose of randomized study medication in the treatment period. Only those participants with data available at the specified time point were included in the analysis.

Time frame:
Baseline (BL) and Day 85
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Visit 8)
LitersUmeclidinium/Vilanterol 62.5/25 µgTiotropium Bromide 18 µg
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Visit 8)0.074 ± 0.0155-0.014 ± 0.0155
Statistical analysis
  • Umeclidinium/Vilanterol 62.5/25 µg vs Tiotropium Bromide 18 µg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.088 · 95% CI 0.045 to 0.131
SecondaryChange From BL in FEV1 at 3 Hours Postdose on Day 84

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in 1 second. FEV1 assessments taken on 0 to 3 hour on Day 84 (pre-dose, 5 minutes (min), 15 min, 30 min, 1 hour, and 3 hour post-dose). Pre-dose was the reading obtained at 24 hours after the previous day's dose (Day 83 dose). BL is defined as mean of the values measured 23 hour and 24 hour after dosing prior to Day 1 (ie. after the last OL tiotropium dosing and prior to the randomized dose). Change from BL is defined as the post-BL value minus the BL value. Analysis performed using mixed model repeated measures with covariates of treatment, BL FEV1, center group, 24 hour subset flag, time, time by treatment interaction and time by BL interaction. Only those participants with data available at the specified time point were included in the analysis.

Time frame:
Baseline and Day 84
Reported as:
Least squares mean · Liters
Change From BL in FEV1 at 3 Hours Postdose on Day 84
LitersUmeclidinium/Vilanterol 62.5/25 µgTiotropium Bromide 18 µg
Change From BL in FEV1 at 3 Hours Postdose on Day 840.164 ± 0.01780.091 ± 0.0177
Statistical analysis
  • Umeclidinium/Vilanterol 62.5/25 µg vs Tiotropium Bromide 18 µg · Mixed Models Analysis · p = 0.004 · Mean difference (final values): 0.073 · 95% CI 0.024 to 0.122

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected over a period of a maximum of 94 days starting from Day 1 of treatment until the follow-up contact.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Umeclidinium/Vilanterol 62.5/25 µg—7/247 (2.8%)34/247 (13.8%)
Tiotropium Bromide 18 µg—6/247 (2.4%)34/247 (13.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventUmeclidinium/Vilanterol 62.5/25 µgTiotropium Bromide 18 µg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2472/247
PneumothoraxRespiratory, thoracic and mediastinal disorders1/2470/247
Myocardial infarctionCardiac disorders1/2470/247
Atrial flutterCardiac disorders1/2470/247
PneumoniaInfections and infestations1/2470/247
AppendicitisInfections and infestations1/2470/247
Benign prostatic hyperplasiaReproductive system and breast disorders1/2471/247
Cervical vertebral fractureInjury, poisoning and procedural complications0/2471/247
DehydrationMetabolism and nutrition disorders0/2471/247
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2471/247
Most frequent other events
Most frequent other events
EventUmeclidinium/Vilanterol 62.5/25 µgTiotropium Bromide 18 µg
NasopharyngitisInfections and infestations18/24717/247
HeadacheNervous system disorders16/24718/247

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Umeclidinium/Vilanterol 62.5/25 µgTiotropium Bromide 18 µgTotal
Mean64.5 ± 8.7164.3 ± 8.7464.4 ± 8.71
Sex: Female, Male
Sex: Female, Male(Participants)Umeclidinium/Vilanterol 62.5/25 µgTiotropium Bromide 18 µgTotal
Female8487171
Male163160323
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Umeclidinium/Vilanterol 62.5/25 µgTiotropium Bromide 18 µgTotal
African American/African Heritage246
Asian - Central/South Asian Heritage112
White - Arabic/North African Heritage448
White - White/Caucasian/European Heritage239237476
White - Mixed Race112
08

Study locations

64 sites
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    La Plata, Buenos Aires 1900, Argentina
  • GSK Investigational Site
    San Rafael, Mendoza 5600, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, 4000, Argentina
  • GSK Investigational Site
    Tallinn, 10117, Estonia
  • GSK Investigational Site
    Tallinn, 10138, Estonia
  • GSK Investigational Site
    Tallinn, 13419, Estonia
  • GSK Investigational Site
    Tallinn, 13619, Estonia
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Potsdam, Brandenburg 14467, Germany
  • GSK Investigational Site
    Potsdam, Brandenburg 14469, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30173, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44263, Germany
  • GSK Investigational Site
    Dueren, Nordrhein-Westfalen 52349, Germany
  • GSK Investigational Site
    Witten, Nordrhein-Westfalen 58452, Germany
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Berlin, 12157, Germany
  • GSK Investigational Site
    Berlin, 13086, Germany
  • GSK Investigational Site
    Berlin, 13581, Germany
  • GSK Investigational Site
    Gyeonggi-do, 410-719, Korea, Republic of
  • GSK Investigational Site
    Bodø, 8005, Norway
  • GSK Investigational Site
    Hamar, 2317, Norway
  • GSK Investigational Site
    Haugesund, 5528, Norway
  • GSK Investigational Site
    Kløfta, 2040, Norway
  • GSK Investigational Site
    Stavanger, 4005, Norway
  • GSK Investigational Site
    Tønsberg, 3116, Norway
  • GSK Investigational Site
    Blagoveshchensk, 675000, Russian Federation
  • GSK Investigational Site
    Chelyabinsk, 454021, Russian Federation
  • GSK Investigational Site
    Irkutsk, 664005, Russian Federation
  • GSK Investigational Site
    Kemerovo, 650000, Russian Federation
  • GSK Investigational Site
    Kemerovo, 650002, Russian Federation
  • GSK Investigational Site
    Moscow, 125315, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630102, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 194356, Russian Federation
  • GSK Investigational Site
    Bellville, 7530, South Africa
  • GSK Investigational Site
    Bloemfontein, 9301, South Africa
  • GSK Investigational Site
    Durban, 4001, South Africa
  • GSK Investigational Site
    Gatesville, 7764, South Africa
  • GSK Investigational Site
    Middelburg, 1501, South Africa
  • GSK Investigational Site
    Mowbray, 7700, South Africa
  • GSK Investigational Site
    Somerset West, 7130, South Africa
  • GSK Investigational Site
    Borås, SE-506 30, Sweden
  • GSK Investigational Site
    Göteborg, SE-413 90, Sweden
  • GSK Investigational Site
    Luleå, SE-971 89, Sweden
  • GSK Investigational Site
    Lund, SE-221 85, Sweden
  • GSK Investigational Site
    Stockholm, SE-111 57, Sweden
  • GSK Investigational Site
    Örebro, SE-703 62, Sweden
  • GSK Investigational Site
    Kharkiv, 61124, Ukraine
  • GSK Investigational Site
    Kiev, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 03038, Ukraine
  • GSK Investigational Site
    Kyiv, 03049, Ukraine
  • GSK Investigational Site
    Kyiv, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, Ukraine
  • GSK Investigational Site
    Mykolayiv, 54003, Ukraine
  • GSK Investigational Site
    Vinnytsya, 21001, Ukraine
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jul 2015, 10 months.

Results were first posted in Feb 2016, 7 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 10 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2013
First posted
Jul 15, 2013
StartActual
Sep 15, 2014
Primary completionActual
Jul 22, 2015
CompletionActual
Jul 22, 2015
Results first posted
Feb 25, 2016
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01899742
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 15, 2013
Start date
Sep 15, 2014
Primary completion
Jul 22, 2015
Completion
Jul 22, 2015
Results posted
Feb 25, 2016
Last update
Jan 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion